Table 2.
WHO guideline for cryptococcosis in HIV-infected patients, 2022
| Phase | Induction | Consolidation | Maintenance | |
|---|---|---|---|---|
| Option | Week 1 | Week 2 | Weeks 8–10 | Onwards |
| 1—Preferred | ||||
| Single-dose liposomal amphotericin Ba plus 14 days of flucytosineb combined with fluconazole | Fluconazole 800 mg/day | Fluconazole 200 mg/day | ||
| 2—If liposomal amphotericin is unavailable | ||||
| Amphotericin B deoxycholatec plus flucytosine | Fluconazole 1200 mg/day | Fluconazole 800 mg/day | Fluconazole 200 mg/day | |
| 3—If no amphotericin formulation is available | ||||
| Fluconazole 1200 mg/day plus flucytosineb | Fluconazole 800 mg/day | Fluconazole 200 mg/day | ||
| 4—If flucytosine is unavailable | ||||
| Liposomal amphotericin Bd plus fluconazole 1200 mg/day | Fluconazole 800 mg/day | Fluconazole 200 mg/day | ||
| 5—If liposomal amphotericin B and flucytosine are unavailable | ||||
| Amphotericin B deoxycholatec plus fluconazole 1200 mg/day | Fluconazole 800 mg/day | Fluconazole 200 mg/day | ||
All doses refer to adults; for children, refer to the WHO guidelines
WHO World Health Organization
a10 mg/kg
b100 mg/kg/day in 4 divided doses
c1 mg/kg/day
d3–4 mg/kg/day